BATTLE researchers identify new biomarkers for EGFR inhibition
Scientists are continuing their work on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial — known more commonly as the BATTLE trial — and presented updated results at the AACR 102nd Annual Meeting 2011, held here April 2-6. John Heymach, M.D., Ph.D., associate professor of thoracic, head and neck medical oncology at The University of Texas MD Anderson Cancer Center, said this update details the "discovery phase" of the ongoing program.
"Last year, we presented results on pre-specified markers to determine how effective they would be at predicting response to EGFR inhibition. This year we worked in the other direction to try to discover and test novel gene markers that hadn't been pre-specified," said Heymach.
Researchers performed gene expression profiling and core needle biopsies on 101 patients in the BATTLE trial. They found that the presence of an EMT (epithelial-to-mesenchymal signature) and the presence of a novel five gene signature including LCN2 were predictive of response to erlotinib, including patients with wild-type EGFR, as measured by disease control rate and progression-free survival.
Heymach said thus far new markers were identified retrospectively in the BATTLE protocol. The upcoming BATTLE 2 protocol will test the predictive value of these gene signatures prospectively.
"The hope is that we'll be able to predict who will respond to EGFR inhibition with erlotinib, particularly among patients who do not have an EGFR mutation. We currently don't have any predictive markers for this group of patients. We also think a similar approach can be applied to other drugs," he said.
The first results of BATTLE, which were presented at the AACR 101st Annual Meeting 2010, are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting at this year's Annual Meeting on Sunday, April 3.
The updated "discovery phase" results of the BATTLE trial will be presented during a press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can participate by using the following information:
- U.S. & Canada: (888) 647-7462
- International: (201) 604-0169
- Access Code: 244078
Source: American Association for Cancer Research
Articles on the same topic
- Serum test could identify lung cancer in people who never smokedMon, 4 Apr 2011, 13:05:56 UTC
- Nicotine does not promote lung cancer growth in mouse modelsMon, 4 Apr 2011, 12:36:29 UTC
- Lung cancer risk rises in the presence of HPV antibodiesMon, 4 Apr 2011, 12:36:22 UTC
- The AACR increases focus on clinical trials Sat, 2 Apr 2011, 22:34:34 UTC
- Target for lung cancer chemoprevention identifiedSat, 2 Apr 2011, 22:34:27 UTC
Other sources
- Serum test could identify lung cancer in people who never smokedfrom PhysorgMon, 4 Apr 2011, 14:31:51 UTC
- Nicotine does not promote lung cancer growth in mouse modelsfrom PhysorgMon, 4 Apr 2011, 13:31:11 UTC
- Lung cancer risk rises in the presence of HPV antibodiesfrom PhysorgMon, 4 Apr 2011, 13:31:09 UTC
- Nicotine does not promote lung cancer growth in mouse modelsfrom Science DailyMon, 4 Apr 2011, 13:30:22 UTC
- Lung cancer risk rises in the presence of HPV antibodiesfrom Science DailyMon, 4 Apr 2011, 13:30:19 UTC
- BATTLE researchers identify new biomarkers for EGFR inhibitionfrom PhysorgSat, 2 Apr 2011, 22:31:06 UTC
- Target for lung cancer chemoprevention identifiedfrom PhysorgSat, 2 Apr 2011, 22:31:01 UTC
- BATTLE researchers identify new biomarkers for EGFR inhibitionfrom Science DailySat, 2 Apr 2011, 22:30:34 UTC
- Target for lung cancer chemoprevention identifiedfrom Science DailySat, 2 Apr 2011, 22:30:30 UTC